Evidence map›Paper›PMID 41095685›Full record

ArticleDiagnostics (Basel, Switzerland)2025

AI-Based 3D-Segmentation Quantifies Sarcopenia in Multiple Myeloma Patients.

Thuy-Duong Do, Tobias Nonnenmacher, Marieke Burghardt, Stefanie Zschaebitz, Marina Hajiyianni, Elias Karl Mai, Marc-Steffen Raab, Carsten Müller-Tidow, Hans-Ulrich Kauczor, Hartmut Goldschmidt and 1 more

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Thuy-Duong DoClinic of Diagnostic and Interventional Radiology (DIR), Heidelberg University Hospital, 69120 Heidelberg, Germany.ORCID 0000-0003-2561-3404
Tobias NonnenmacherClinic of Diagnostic and Interventional Radiology (DIR), Heidelberg University Hospital, 69120 Heidelberg, Germany.
Marieke BurghardtGerman-Speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, 69120 Heidelberg, Germany.
Stefanie ZschaebitzNational Center for Tumor Diseases (NCT), Department of Medical Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Marina HajiyianniGerman-Speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, 69120 Heidelberg, Germany.
Elias Karl MaiGerman-Speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, 69120 Heidelberg, Germany.
Marc-Steffen RaabGerman-Speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, 69120 Heidelberg, Germany.
Carsten Müller-TidowHeidelberg Myeloma Center, Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Medical Faculty Heidelberg, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Hans-Ulrich KauczorClinic of Diagnostic and Interventional Radiology (DIR), Heidelberg University Hospital, 69120 Heidelberg, Germany.
Hartmut GoldschmidtGerman-Speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, 69120 Heidelberg, Germany.ORCID 0000-0003-0961-0035
Ulrike DapuntGerman-Speaking Myeloma Multicenter Group (GMMG), Heidelberg University Hospital, 69120 Heidelberg, Germany.ORCID 0000-0001-7396-6074

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

induction chemotherapyintelligent systemsmultiple myelomasarcopeniatomographyX-ray computed

Identifiers

PMID41095685
PMCPMC12523729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.